B.Riley Reiterates Capricor (CAPR) at Buy, 'believe Deramiocel peak sales could likely exceed $1B'
Tweet Send to a Friend
B.Riley analyst Madison El-Saadi reiterated a Buy rating on Capricor Therapeutics (NASDAQ: CAPR).The analyst commented: 'Buy-rated CAPR disclosed Ph3 HOPE-3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
